Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 51 to 75 of 122

TitleReference numberPublishedLast updated
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Liposuction for chronic lipoedemaHTG618
Liposuction for chronic lymphoedemaHTG622
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Lumella point-of-care test for assessing pre-eclampsia riskMIB287
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adultsNG215
Mental wellbeing at workNG212
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Microwave ablation for primary or metastatic cancer in the lungHTG609
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Multiple sclerosis in adults: managementNG220
Neonatal parenteral nutritionQS205
Nerve graft for corneal denervationHTG629
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Odevixibat for treating progressive familial intrahepatic cholestasisHST17
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Otitis media (acute): antimicrobial prescribingNG91
Palforzia for treating peanut allergy in children and young peopleTA769
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Pelvic floor dysfunction: prevention and non-surgical managementNG210
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801

Results per page

  1. 10
  2. 25
  3. 50
  4. All